Preapproval reviews are conducted by UniCare’s Managed Care department or by AIM Specialty HealthSM, a UniCare-affiliated company that provides support for the preapproval process. Our Provider Reference Sheet identifies which services are reviewed by UniCare and which are reviewed by AIM and how much notice is required (see below).
Use this resource as a convenient reference for member copays, notification requirements for preapprovals, and selected procedures for pre-review. View the preapproval requirements effective September 15, 2019.
You can also visit our member page to view notification requirements for preapprovals documents provided to members. Please refer to the applicable member handbook for more information on plan benefits, conditions, limitations and exclusions.
For UniCare reviews
|UniCare Provider Services 800-442-9300|
For AIM reviews
|Contact AIM directly:
For Express Scripts reviews of certain non-oncology specialty drugs
About AIM’s web-based application – UniCare’s partnership with AIM lets our providers use AIM’s web-based application for services reviewed by AIM. Providers can log into the AIM application and complete the intake process for certain procedures, as noted in our Provider Reference Sheet (see above). In many cases, the entire review and approval process can be done online. Providers who already use AIM’s web application will not have to re-register for UniCare.
Express Scripts, the administrator for the prescription drug plan for UniCare's non-Medicare members, covers and dispenses self- or office-administered specialty drugs (non-oncology). In addition, some specialty drugs require review and dispensing by Express Scripts, for non-Medicare members only. The list of these specialty drugs is updated periodically and posted on this site. View the current list effective January 1, 2020.
Expanded review required for certain infused specialty drugs
If a non-Medicare member will be getting infusions of certain non-oncology specialty drugs in a hospital outpatient setting, an expanded review will be conducted to review both the drug for clinical appropriateness and the level of care/site of service. See the Provider Reference Sheet above for a link to the lists of specialty drugs that will require level of care review.
UniCare now reviewing certain specialty drugs previously reviewed by AIM – Effective September 15, 2019, UniCare began reviewing all oncology specialty drugs and certain non-oncology specialty drugs that were previously reviewed by AIM. Certain other non-oncology drugs will continue to be reviewed by Express Scripts.
Updates to AIM guidelines for cardiac imaging effective January 28, 2019 – Beginning with dates of service on or after January 28, 2019, AIM Specialty Health® is revising its guidelines for certain cardiac imaging procedures. You can also view the complete text of the updated guidelines at www.aimspecialtyhealth.com.
An expanded review will be required for certain infused specialty drugs – If a non-Medicare member will be getting infusions of certain non-oncology specialty drugs in a hospital outpatient setting, an expanded review will be conducted to review both the drug for clinical appropriateness and the level of care/site of service. Learn more about this change.
See the Provider Reference Sheet above for a link to the lists of specialty drugs that will require level of care review.